Overview

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Status:
Completed

Trial end date:
2019-02-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab